EMPAVELI (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced ...

EMPAVELI®(pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada WALTHAM, Mass., April 09, 2026 (GLOBE NEWSWIRE)-- Swedish Orphan Biovitrum ...

WALTHAM, Mass., April 09, 2026 (GLOBE NEWSWIRE)-- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that Health Canada has approved EMPAVELI ® (pegcetacoplan), a complement ...

A transplant is often preferable to dialysis. While dialysis is a life-saving measure, it’s a lifetime commitment, and it has potential risks and complications. Your doctor determines whether you’re ...

C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) are rare and progressive kidney diseases, caused by problems in the immune system. They are two distinct ...

Apellis Pharmaceuticals (APLS) stock fell 31% over the past year despite securing FDA approval for EMPAVELI in rare kidney diseases. Apellis hit 152 patient start forms by September. Management’s year ...

Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan reduced proteinuria in patients with rare complement-mediated glomerular diseases vs. placebo.

Empaveli is prescribed to treat paroxysmal nocturnal hemoglobinuria (PNH) in adults, as well as C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in ...